相关实验视频

Updated: May 23, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

在接受阿片类药物治疗癌症的患者中进行长度尿液药物测试疼痛

Amanda V Gusovsky Chevalier¹, Julia L Agne², Laura J Rush¹

¹The Center for the Advancement of Team Science (AVGC, GDT, ASM), Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, Ohio, USA.

Journal of pain and symptom management

|March 7, 2025

概括

接受阿片类药物治疗的癌症患者的尿液药物测试 (UDT) 显示,15.1%的患者有无法解释的结果,在息治疗期间检测到非处方药物或缺失处方药物. 持续的UDT对于患者安全和遵守监测至关重要.

科学领域:

在瘤学瘤学.
抚慰性护理是一种缓解性护理.
药理学药理学是指药理学的学科.

背景情况:

建议在治疗阿片类药物治疗癌症疼痛的患者进行尿液药物测试 (UDT),以监测非处方药物的使用和治疗坚持.
在接受阿片类药物治疗癌症疼痛管理的患者中进行UDT的最佳频率尚不清楚.

研究的目的:

描述在接受门诊息治疗 (PC) 的癌症成年患者的初始和随后的尿液药物测试 (UDTs) 的结果.
分析不明原因的UDT结果的发生和时间,包括非处方药物的存在和没有处方药的缺失.

主要方法:

在第三级癌症中心进行了一项回顾性研究,分析了2017年7月至2019年6月期间在门诊息治疗诊所的成年患者的数据.
结果包括第一个不明原因的UDT结果的时间,分类为非处方物质的存在或没有处方物质的存在.
逆卡普兰-梅尔生存曲线被用来绘制这些结果,并总结了涉及的物质.

主要成果:

该研究包括1,141名患者和2,459名UDT,平均每个患者的UDT为2.4.
15.1%的患者表现出至少一个不明原因的UDT,其中45%的患者在基线UDT时被检测到.
在24个月后,检测非处方药物的累积概率为19.7%,没有处方药的概率为18.6%. 可卡因和氧化分别是最频繁检测到的非处方和缺席物质.

结论:

无法解释的UDT结果发生在息治疗期间的不同时间点,支持基线和正在进行的UDT的实用性.
定期的UDT对于优化患者安全和监测接受阿片类药物治疗的癌症患者的药物坚持至关重要.
息护理提供者应考虑在息护理的整个过程中继续使用UDT.

关键词:

尿液药物查尿液药物查癌症癌症癌症癌症癌症抚慰性护理是一种缓解性护理.药物使用障碍物使用障碍物.

更多相关视频

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

相关概念视频

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...